Skip to content

Author

Katharina Epp

We have 1 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.

These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.

A. Tuettenberg, L. Ruhnke, J. Schlöder et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.